Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discuss the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective VMAT2 inhibitor treatments have only been available since 2017.
Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?
Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.
A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.
Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.
Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.
Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.
Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.
GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.
Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.
Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.
Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.
Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.
Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.
A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.
Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.
Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.
In this interview, Chris Elder, PharmD, BCOP, discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.
In this interview, Sonia Amin Thomas, PharmD, BCOP, AFMCP, INHC, discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.
Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.
Pharmacy Times speaks with Caitlin Jones, PHD, on opioids, spinal cord stimulators, and treatment-related harms in chronic low back pain.
Sandie Kueker, RPh, shares how advocacy and a strong medication synchronization program have helped her independent pharmacies expand clinical services and better serve rural communities.
Emily Flaugher discusses how Health Mart Atlas tools and emerging legislative momentum are helping independent pharmacies navigate reimbursement challenges and unlock new revenue opportunities.
This OPC interview discusses emerging personalized immunotherapy approaches in melanoma, evolving toxicity management strategies, and the future role of cancer vaccines in cutaneous oncology.
Pharmacy streamlines bispecific programs with tailored operations, scheduling, order sets, and reimbursement checkpoints.
This OPC interview discusses the growing importance of molecular testing, care coordination, and oral oncology therapies in optimizing outcomes for patients with gastrointestinal malignancies.
The growing importance of comprehensive biomarker testing, toxicity management, and the expanding role of targeted therapies in early-stage thoracic malignancies.
Crystal Lennartz, PharmD, MBA, discusses independent pharmacy resilience, recent industry recognitions, and new tools announced at McKesson ideaShare 2026 to support pharmacy growth and transparency.
This OPC interview discusses emerging standards of care in genitourinary cancers, the growing role of molecular testing and minimal residual disease monitoring, and how oncology pharmacists can optimize treatment management.
This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.
